| Year |
Citation |
Score |
| 2007 |
Kremer BE, Adang LA, Macara IG. Septins regulate actin organization and cell-cycle arrest through nuclear accumulation of NCK mediated by SOCS7. Cell. 130: 837-50. PMID 17803907 DOI: 10.1016/J.Cell.2007.06.053 |
0.459 |
|
| 2005 |
Kremer BE, Haystead T, Macara IG. Mammalian septins regulate microtubule stability through interaction with the microtubule-binding protein MAP4. Molecular Biology of the Cell. 16: 4648-59. PMID 16093351 DOI: 10.1091/Mbc.E05-03-0267 |
0.478 |
|
| 2003 |
Yoshida T, Sinha S, Dandré F, Wamhoff BR, Hoofnagle MH, Kremer BE, Wang DZ, Olson EN, Owens GK. Myocardin is a key regulator of CArG-dependent transcription of multiple smooth muscle marker genes. Circulation Research. 92: 856-64. PMID 12663482 DOI: 10.1161/01.Res.0000068405.49081.09 |
0.348 |
|
| 2003 |
Sheffield PJ, Oliver CJ, Kremer BE, Sheng S, Shao Z, Macara IG. Borg/septin interactions and the assembly of mammalian septin heterodimers, trimers, and filaments. The Journal of Biological Chemistry. 278: 3483-8. PMID 12446710 DOI: 10.1074/Jbc.M209701200 |
0.49 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2016 |
Borthakur G, Dawson MA, Stein EM, Karadimitris A, Huntly BJ, Dickinson MJ, Chaidos A, Horner T, Brennan J, Baron J, Kremer BE, Dhar A. A Phase I/II Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Subjects with Relapsed, Refractory Hematologic Malignancies Blood. 128: 5223-5223. DOI: 10.1182/BLOOD.V128.22.5223.5223 |
0.186 |
|
| 2019 |
Bell CC, Fennell KA, Chan YC, Rambow F, Yeung MM, Vassiliadis D, Lara L, Yeh P, Martelotto LG, Rogiers A, Kremer BE, Barbash O, Mohammad HP, Johanson TM, Burr ML, et al. Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia. Nature Communications. 10: 2723. PMID 31222014 DOI: 10.1038/S41467-019-10652-9 |
0.142 |
|
| 2017 |
Sparano JA, Cescon DW, Oliveira M, Stover DG, Tan-Chiu E, Kremer BE, Barbash O, Wu Y, Mathew L, Cunningham EA, Carpenter CL, Ballas MS, Dhar A. A phase I/II dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with fulvestrant in subjects with ER+ breast cancer. Journal of Clinical Oncology. 35: TPS1114-TPS1114. DOI: 10.1200/JCO.2017.35.15_SUPPL.TPS1114 |
0.134 |
|
| 2019 |
Siu L, Rasco D, Vinay SP, Romano PM, Menis J, Opdam F, Heinhuis K, Egger J, Gorman S, Parasrampuria R, Wang K, Kremer B, Gounder M. METEOR-1: A phase I study of GSK3326595, a first-in-class protein arginine methyltransferase 5 (PRMT5) inhibitor, in advanced solid tumours Annals of Oncology. 30: v159. DOI: 10.1093/annonc/mdz244 |
0.12 |
|
| 2019 |
Watts JM, Bradley TJ, Thomassen A, Brunner AM, Minden MD, Papadantonakis N, Abedin S, Baines AJ, Barbash O, Gorman S, Kremer BE, Borthakur GM. A Phase I/II Study to Investigate the Safety and Clinical Activity of the Protein Arginine Methyltransferase 5 Inhibitor GSK3326595 in Subjects with Myelodysplastic Syndrome and Acute Myeloid Leukemia Blood. 134: 2656-2656. DOI: 10.1182/blood-2019-130337 |
0.115 |
|
| 2018 |
Dickinson M, Kamdar M, Huntly BJ, Fernández De Larrea C, Cordoba R, Mateos M, Alegre A, Kim W, Kim JS, Dawson M, Yeh PS, Basheer F, Gallipoli P, Chaidos A, Martín A, ... ... Kremer BE, et al. A Phase I Study of Molibresib (GSK525762), a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of a Phase I/II Open Label Single Agent Study in Subjects with Non-Hodgkin's Lymphoma (NHL) Blood. 132: 1682-1682. DOI: 10.1182/BLOOD-2018-99-117089 |
0.111 |
|
| 2021 |
Cousin S, Blay JY, Braña Garcia I, de Bono JS, Le Tourneau C, Moreno V, Trigo J, Hann CL, Azad AA, Im SA, Cassier PA, French CA, Italiano A, Keedy VL, Plummer R, ... ... Kremer BE, et al. Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of NUT carcinoma and other cancers: results of a phase I/II open-label, dose escalation study. International Journal of Cancer. PMID 34724226 DOI: 10.1002/ijc.33861 |
0.101 |
|
| 2014 |
Stoeck A, Lejnine S, Truong A, Pan L, Wang H, Zang C, Yuan J, Ware C, MacLean J, Garrett-Engele PW, Kluk M, Laskey J, Haines BB, Moskaluk C, Zawel L, ... ... Kremer BE, et al. Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma. Cancer Discovery. 4: 1154-67. PMID 25104330 DOI: 10.1158/2159-8290.CD-13-0830 |
0.1 |
|
| 2022 |
Dawson MA, Borthakur G, Huntly B, Karadimitris A, Alegre A, Chaidos A, Vogl DT, Pollyea DA, Davies FE, Morgan GJ, Glass J, Kamdar M, Mateos Manteca MV, Tovar N, Yeh P, ... ... Kremer BE, et al. A phase I/II open-label study of molibresib for the treatment of relapsed/refractory hematologic malignancies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 36350312 DOI: 10.1158/1078-0432.CCR-22-1284 |
0.099 |
|
| 2020 |
Riddell K, Patel A, Collins G, Zhou Y, Schramek D, Kremer BE, Ferron-Brady G. An Adaptive Physiologically Based Pharmacokinetic-Driven Design to Investigate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of Molibresib (GSK525762) in Healthy Female Volunteers. Journal of Clinical Pharmacology. PMID 32820548 DOI: 10.1002/jcph.1711 |
0.094 |
|
| 2021 |
Nooka AK, Weisel K, van de Donk NW, Routledge D, Otero PR, Song K, Quach H, Callander N, Minnema MC, Trudel S, Jackson NA, Ahlers CM, Im E, Cheng S, Smith L, ... ... Kremer BE, et al. Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design. Future Oncology (London, England). PMID 33682447 DOI: 10.2217/fon-2020-1269 |
0.089 |
|
| 2020 |
Trudel S, Davis R, Lewis NM, Bakshi KK, Chopra B, Montes de Oca R, Ferron-Brady G, Eliason L, Kremer BE, Gupta I, Wu FS. DREAMM-8: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin with Pomalidomide and Dexamethasone (B-Pd) Vs Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Blood. 136: 4-4. DOI: 10.1182/blood-2020-139785 |
0.08 |
|
| 2020 |
Richardson PG, Nooka A, Quach H, Trudel S, Routledge D, Song K, Nahi H, Paul S, Khan J, Brouch M, Ferron-Brady G, Yeakey A, Shelton C, Montes de Oca R, Smith LM, ... ... Kremer BE, et al. Dreamm-5 Platform Trial: Belantamab Mafodotin (Belamaf) in Combination with Four Different Novel Agents in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Blood. 136: 1-2. DOI: 10.1182/blood-2020-139182 |
0.067 |
|
| 2020 |
Cousin S, Blay J, Braña Garcia I, De Bono JS, Le Tourneau C, Moreno V, Trigo JM, Hann CL, Azad A, Im S, Ferron-Brady G, Datta A, Wu Y, Horner T, Kremer BE, et al. BET inhibitor molibresib for the treatment of advanced solid tumors: Final results from an open-label phase I/II study. Journal of Clinical Oncology. 38: 3618-3618. DOI: 10.1200/jco.2020.38.15_suppl.3618 |
0.067 |
|
| 2023 |
Iida S, Sunami K, Mishima Y, Fujii T, Kato H, Terao T, Matsuzawa Y, Matsubara M, Crossman T, Kremer BE, Gupta I. Safety, pharmacokinetics, and efficacy of belantamab mafodotin monotherapy in Japanese patients with relapsed or refractory multiple myeloma: DREAMM-11. International Journal of Hematology. PMID 37668832 DOI: 10.1007/s12185-023-03652-5 |
0.066 |
|
| 2020 |
Popat R, Nooka A, Stockerl-Goldstein K, Abonour R, Ramaekers R, Khot A, Forbes A, Lee C, Augustson B, Spencer A, Mateos M, Chopra B, Rogers R, Smith DA, Davidge J, ... ... Kremer BE, et al. DREAMM-6: Safety, Tolerability and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM) Blood. 136: 19-20. DOI: 10.1182/blood-2020-139332 |
0.06 |
|
| 2015 |
Tsai DE, Luskin MR, Kremer BE, Chung AK, Arnoldi S, Paralkar VR, Nasta SD, Stadtmauer EA, Schuster SJ, Xavier M. A pilot trial of quantitative Epstein-Barr virus polymerase chain reaction in patients undergoing treatment for their malignancy: potential use of Epstein-Barr virus polymerase chain reaction in multiple cancer types. Leukemia & Lymphoma. 56: 1530-2. PMID 25219594 DOI: 10.3109/10428194.2014.963577 |
0.048 |
|
| 2021 |
Anderson KC, Auclair D, Adam SJ, Agarwal A, Anderson M, Avet-Loiseau H, Bustoros M, Chapman J, Connors DE, Dash A, Di Bacco A, Du L, Facon T, Flores-Montero J, Gay F, ... ... Kremer BE, et al. Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34321279 DOI: 10.1158/1078-0432.CCR-21-1059 |
0.038 |
|
| 2017 |
Kremer B, Tsai DE, Debonera F, Cohen PL, Schuster SJ. Spontaneous remission of acute myeloid leukemia after discontinuation of lenalidomide. Leukemia & Lymphoma. 1-3. PMID 28695787 DOI: 10.1080/10428194.2017.1347652 |
0.03 |
|
| 2012 |
Kremer BE, Reshef R, Misleh JG, Christie JD, Ahya VN, Blumenthal NP, Kotloff RM, Hadjiliadis D, Stadtmauer EA, Schuster SJ, Tsai DE. Post-transplant lymphoproliferative disorder after lung transplantation: a review of 35 cases. The Journal of Heart and Lung Transplantation : the Official Publication of the International Society For Heart Transplantation. 31: 296-304. PMID 22112992 DOI: 10.1016/j.healun.2011.10.013 |
0.019 |
|
| 2023 |
Ficek J, Kalaitzaki E, Yuan SS, Tosolini A, Du L, Kremer BE, Davy K, Zhou H, Chen TT. Association of Minimal Residual Disease Negativity Rates With Progression Free Survival in Frontline Therapy Trials for Newly Diagnosed Multiple Myeloma: A Meta-analysis. Clinical Lymphoma, Myeloma & Leukemia. PMID 36907767 DOI: 10.1016/j.clml.2023.02.005 |
0.016 |
|
| Hide low-probability matches. |